Veeva Systems

Lotus Clinical Research Expands Partnership with Veeva to Accelerate Clinical Trials

Retrieved on: 
вторник, мая 30, 2023
Partnership, CNS, CTMS, Veeva Systems, Documentation, CDMS, Pain, Knowledge, Growth, NYSE, Lotus, EDC, Pharmaceutical industry, Nursing

NEW PROVIDENCE, N.J. and BARCELONA, Spain, May 30, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research expanded its partnership with Veeva and broadened its adoption of Veeva Vault Clinical Suite, a strategic move to strengthen its service delivery and efficiency. This builds on Lotus' existing use of Vault Clinical Suite to implement swifter and more connected studies. The successful incorporation of Veeva Vault CDMS, Veeva Vault eTMF, and Veeva Vault CTMS has effectively scaled Lotus' trial operations while sustaining the highest quality standards. With a unified clinical ecosystem, Lotus has significantly reduced study startup time.

Key Points: 
  • NEW PROVIDENCE, N.J. and BARCELONA, Spain, May 30, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research expanded its partnership with Veeva and broadened its adoption of Veeva Vault Clinical Suite , a strategic move to strengthen its service delivery and efficiency.
  • The successful incorporation of Veeva Vault CDMS , Veeva Vault eTMF , and Veeva Vault CTMS has effectively scaled Lotus' trial operations while sustaining the highest quality standards.
  • Lotus President, Bill Martin, elaborated on the benefits of the partnership with Veeva, "This collaboration enables Lotus to conduct a higher volume of clinical trials while improving coordination with sponsors and clinical trial sites.
  • "We're proud to grow our five-plus year partnership with Lotus, bringing together their experience and knowledge executing complex clinical trials with our technology expertise," said Jon Young, director, Veeva Vault Clinical strategy.

Kristin Judge Joins Emmes as Chief Growth Officer

Retrieved on: 
четверг, мая 25, 2023
Informatics, Public sector, Labcorp Drug Development, PPD, Growth, Contract research organization, Labcorp, Investment, Public, Fine chemical, EMMS International, Veeva Systems

, May 25, 2023 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Kristin Judge has joined as its chief growth officer, a newly created executive leadership position.

Key Points: 
  • , May 25, 2023 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Kristin Judge has joined as its chief growth officer, a newly created executive leadership position.
  • Emmes Chief Executive Officer Dr. Christine Dingivan said, "Kristin's experience is a perfect fit for Emmes, given her accomplishments across CRO and life sciences sales.
  • In addition to Judge, these include Becky Marson as chief people and performance officer; Matt Honan, vice president and global head of corporate development; Wendy Buckland, chief operating officer; and Ching Tian, chief innovation officer.
  • Dr. Dingivan noted, "I'm confident that the establishment of the chief growth officer position to spearhead our sales efforts and the recruitment of Kristin, given her 15 years of experience in both CRO and life sciences sales, will add immediate value to Emmes."

Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications

Retrieved on: 
среда, мая 24, 2023
DSM-IV codes, CDMO, Documentation, GxP, Patient, Cancer, Ecosystem, NYSE, Medical device, Veterinary medicine, Veeva Systems

PLEASANTON, Calif., May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva's unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance. 

Key Points: 
  • PLEASANTON, Calif., May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations.
  • Minaris Regenerative Medicine will use Veeva's unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance.
  • "With Veeva Vault Quality Suite applications, we are well-positioned for GxP document control and continuous quality improvement.
  • "Minaris Regenerative Medicine is developing and manufacturing potentially life-changing cell therapies to treat cancers and genetic disorders that do not have any known cures," said Ashley McMillan, senior director, Veeva Vault Quality strategy.

Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications

Retrieved on: 
среда, мая 24, 2023
DSM-IV codes, CDMO, Documentation, GxP, Patient, Cancer, Ecosystem, NYSE, Medical device, Veterinary medicine, Veeva Systems

BARCELONA, Spain, May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva's unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance. 

Key Points: 
  • BARCELONA, Spain, May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations.
  • Minaris Regenerative Medicine will use Veeva's unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance.
  • "With Veeva Vault Quality Suite applications, we are well-positioned for GxP document control and continuous quality improvement.
  • For more on Veeva Vault Quality Suite, visit: veeva.com/Quality Manufacturing
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients

Retrieved on: 
среда, мая 24, 2023
Cloud, GSK, Leo Pharma, Boehringer Ingelheim, Veeva Systems, Syneos Health, Patient, LEO, NYSE, Safety, Fine chemical, Medical device, Pharmaceutical industry, Bayer

BARCELONA, Spain, May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, and Syneos Health are among the speakers at Veeva R&D and Quality Summit, June 6-7 in Madrid, Spain. Industry innovators will share how they leverage next-generation solutions to drive efficiencies that help deliver better patient outcomes.

Key Points: 
  • Veeva R&D and Quality Summit will bring together more than 750 industry professionals to participate in over 40 sessions.
  • "Our top priority is helping the industry deliver innovation that ensures the best possible outcomes for patients," says Rik Van Mol, senior vice president of Veeva Development Cloud.
  • "Veeva R&D and Quality Summit offers industry leaders an ideal forum to connect, exchange ideas, and share strategies that will drive the industry forward."
  • To register for Veeva R&D and Quality Summit visit: veeva.com/eu/Summit
    Learn more about Veeva Development Cloud: veeva.com/eu/DevelopmentCloud
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials

Retrieved on: 
вторник, мая 23, 2023
Heart, Partnership, Clinical trial, Trial of the century, UCB, Patient, NYSE, Pharmaceutical industry, Medical imaging, Veeva Systems

BRUSSELS and PLEASANTON, Calif., May 23, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and UCB, a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency. The collaboration will see UCB adopt Veeva ePRO and Veeva eConsent, to provide a patient-centric, digital experience to study participants and actively influence the strategic direction of these and other applications based on learnings. Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that meet the unique needs of patients.

Key Points: 
  • Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that meet the unique needs of patients.
  • "The partnership between UCB and Veeva presents a significant opportunity to drive progress in clinical study execution," said Iris Loew-Friedrich, executive vice president and chief medical officer at UCB.
  • Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Suite , a set of integrated capabilities that simplify the technology landscape of clinical trials for both clinical operations and clinical data management.
  • "We're excited to partner with UCB to advance patient-centric digital trials," said Veeva CEO Peter Gassner.

UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials

Retrieved on: 
вторник, мая 23, 2023
Heart, Partnership, Clinical trial, Trial of the century, UCB, Patient, NYSE, Pharmaceutical industry, Medical imaging, Veeva Systems

BRUSSELS and PLEASANTON, Calif., May 23, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and UCB, a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency. The collaboration will see UCB adopt Veeva ePRO and Veeva eConsent, to provide a patient-centric, digital experience to study participants and actively influence the strategic direction of these and other applications based on learnings. Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that meet the unique needs of patients.

Key Points: 
  • Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that meet the unique needs of patients.
  • "The partnership between UCB and Veeva presents a significant opportunity to drive progress in clinical study execution," said Iris Loew-Friedrich, executive vice president and chief medical officer at UCB.
  • Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Suite , a set of integrated capabilities that simplify the technology landscape of clinical trials for both clinical operations and clinical data management.
  • "We're excited to partner with UCB to advance patient-centric digital trials," said Veeva CEO Peter Gassner.

New Veeva Link MedTech Provides Real-Time Data to Optimize Scientific Engagement

Retrieved on: 
четверг, мая 18, 2023
Veeva Systems, Automation, NYSE, Medtech, Medical device

PLEASANTON, Calif. , May 18, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Link MedTech, a data application developed for medtech companies to identify scientific experts, personalize engagement, and map activities across the healthcare ecosystem. Built on the same platform as Veeva Link Key People, Link MedTech combines automation and human curation for an accurate, in-depth view of expert profiles in medical devices and diagnostics globally.

Key Points: 
  • Real-time intelligence on key experts helps drive timely, relevant engagement
    PLEASANTON, Calif. , May 18, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Link MedTech , a data application developed for medtech companies to identify scientific experts, personalize engagement, and map activities across the healthcare ecosystem.
  • Built on the same platform as Veeva Link Key People , Link MedTech combines automation and human curation for an accurate, in-depth view of expert profiles in medical devices and diagnostics globally.
  • Link MedTech equips medical affairs and commercial teams with real-time data to effectively engage with customers and key opinion leaders (KOLs).
  • Learn how companies can lead more relevant scientific engagement with experts leveraging Link MedTech at Veeva MedTech Summit , May 30 to June 1 in Chicago.

New Veeva Link MedTech Provides Real-Time Data to Optimize Scientific Engagement

Retrieved on: 
четверг, мая 18, 2023
Veeva Systems, NYSE, Medtech, Automation, Medical device

BARCELONA, Spain, May 18, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Link MedTech, a data application developed for medtech companies to identify scientific experts, personalize engagement, and map activities across the healthcare ecosystem. Built on the same platform as Veeva Link Key People, Link MedTech combines automation and human curation for an accurate, in-depth view of expert profiles in medical devices and diagnostics globally.

Key Points: 
  • Real-time intelligence on key experts helps drive timely, relevant engagement
    BARCELONA, Spain, May 18, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Link MedTech , a data application developed for medtech companies to identify scientific experts, personalize engagement, and map activities across the healthcare ecosystem.
  • Built on the same platform as Veeva Link Key People , Link MedTech combines automation and human curation for an accurate, in-depth view of expert profiles in medical devices and diagnostics globally.
  • Link MedTech equips medical affairs and commercial teams with real-time data to effectively engage with customers and key opinion leaders (KOLs).
  • Learn how companies can lead more relevant scientific engagement with experts leveraging Link MedTech at Veeva MedTech Summit , 30 May to 1 June in Chicago.

PM360 Announces Winners of The Ninth Annual ELITE 100 Awards

Retrieved on: 
вторник, мая 16, 2023
Nexium, Data science, Marketing, GoodRx, EVP, Hospira, Associate, Cardinal Health, Patient, McCourt, HR, Disease, Eli Lilly and Company, Constipation, Attention, Snow, Diagnosis, Entrepreneurship, Growth, Digital marketing, Immunology, FAAN, Engagement, Organon, Caregiver, PR, Ironwood Pharmaceuticals, Exception, COVID-19, IBS-C, Health, ELITE, Boehringer Ingelheim, Abdominal pain, Sustainability, ImmunoGen, RN, Bloating, CO, Providers, Glaucoma, Lead, Mirati Therapeutics, Regulatory science, AstraZeneca, HCP, Gastroesophageal reflux disease, Veeva Systems, Novartis, Omeprazole, Management, Pharmaceutical industry, Beauty salon, Generic drug, Esomeprazole, GERD

NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100. The ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people and teams in the healthcare and life sciences industries based on their career accomplishments. Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.

Key Points: 
  • NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100.
  • Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.
  • PM360 also selects one person as the "Uber ELITE," or the individual among the nominees who best personifies the criteria of a PM360 ELITE.
  • McCourt will serve as the keynote speaker at the annual ELITE 100 Awards Event to celebrate this year's winners.